Temsirolimus is an mTOR-directed antineoplastic agent widely used in oncology and translational research. As a temsirolimus small molecule, it is closely associated with studies of cell growth control, protein translation, and tumor signaling pathways regulated through mTOR. The compound is also identified by CAS 162635-04-3, which is an important reference point in supplier databases, analytical records, and compound verification workflows. According to Pfizer Medical, temsirolimus has the molecular formula C56H87NO16 and a temsirolimus molecular weight of 1030.30. These identifiers, together with temsirolimus structure and temsirolimus smiles, are commonly reviewed by researchers during compound verification, catalog comparison, and assay planning. Pfizer Temsirolimus is also well recognized in the research and clinical literature as a defined reference compound for mTOR-focused studies.
Application of Temsirolimus
In research settings, temsirolimus is applied in oncology, kinase signaling, translational pharmacology, and pathway-focused screening. Its relevance comes from the central role of mTOR in cell proliferation, metabolism, angiogenesis, and tumor progression. Because of that, temsirolimus is often selected for experiments that examine pathway inhibition, biomarker changes, and response patterns in tumor models with PI3K/AKT/mTOR pathway involvement. In sourcing and procurement workflows, searches such as temsirolimus cost and temsirolimus price often appear alongside technical descriptors because buyers are typically evaluating both scientific fit and product traceability before selecting a supplier.
In Vitro
In vitro, temsirolimus has been shown to inhibit mTOR-dependent signaling and suppress growth in treated tumor cells. Pfizer labeling notes that temsirolimus binds to the intracellular protein FKBP-12, and the resulting complex inhibits mTOR activity. This leads to selective disruption of translation of key cell cycle regulatory proteins and results in G1 growth arrest in treated cells. The same source highlights downstream effects involving 4E-BP1 and S6K in the PI3 kinase/AKT pathway, making temsirolimus especially valuable in mechanistic cell-based studies that need a well-characterized mTOR inhibitor.
In Vivo
In vivo, Pfizer documentation reports that temsirolimus inhibited tumor cell growth in nude mouse xenograft models. This connection between defined intracellular mechanism and measurable antitumor response supports its continued use in preclinical oncology research and translational study design. Clinical labeling also reflects its established therapeutic relevance, with Pfizer identifying temsirolimus for advanced renal cell carcinoma, while EMA documentation additionally includes relapsed or refractory mantle cell lymphoma. This broader evidence base strengthens its value as a reference compound for pathway-driven cancer studies.
Biochemical and Physiological Actions
Biochemically, temsirolimus acts through FKBP-12-mediated inhibition of mTOR, a central regulator of cell division and protein translation. When mTOR is blocked, phosphorylation control over downstream translation factors is reduced, influencing proteins tied to cell cycle progression and hypoxia-related signaling. Physiologically, this translates into reduced proliferative signaling and suppression of tumor-supporting processes such as growth and angiogenic response. These well-defined actions explain why temsirolimus structure remains important in technical searches and why the compound is still relevant in discovery programs centered on mTOR biology.
Features and Benefits of Temsirolimus
- Well-documented mTOR mechanism supported by Pfizer technical and clinical sources
- Useful for in vitro signaling studies and in vivo oncology models
- Strong fit for researchers comparing temsirolimus small molecule data across screening and validation workflows
For EBC-27516, temsirolimus offers a combination of recognized pathway relevance, clear structural identity, and strong value for modern oncology research.
